CA3212301A1 - Cell compositions derived from dedifferentiated reprogrammed cells - Google Patents

Cell compositions derived from dedifferentiated reprogrammed cells

Info

Publication number
CA3212301A1
CA3212301A1 CA3212301A CA3212301A CA3212301A1 CA 3212301 A1 CA3212301 A1 CA 3212301A1 CA 3212301 A CA3212301 A CA 3212301A CA 3212301 A CA3212301 A CA 3212301A CA 3212301 A1 CA3212301 A1 CA 3212301A1
Authority
CA
Canada
Prior art keywords
cells
cell
heregulin
cell population
neuregulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3212301A
Other languages
English (en)
French (fr)
Inventor
Alan D. Agulnick
Olivia Kelly
Yuki OHI
Allan Robins
Thomas Schultz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viacyte Inc
Original Assignee
Viacyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/761,078 external-priority patent/US9109245B2/en
Application filed by Viacyte Inc filed Critical Viacyte Inc
Publication of CA3212301A1 publication Critical patent/CA3212301A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3212301A 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells Pending CA3212301A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/761,078 US9109245B2 (en) 2009-04-22 2013-02-06 Cell compositions derived from dedifferentiated reprogrammed cells
US13/761,078 2013-02-06
CA2898431A CA2898431C (en) 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2898431A Division CA2898431C (en) 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells

Publications (1)

Publication Number Publication Date
CA3212301A1 true CA3212301A1 (en) 2014-08-14

Family

ID=50239931

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3212301A Pending CA3212301A1 (en) 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells
CA2898431A Active CA2898431C (en) 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2898431A Active CA2898431C (en) 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells

Country Status (8)

Country Link
EP (1) EP2954045A1 (enExample)
JP (5) JP6517702B2 (enExample)
AU (5) AU2014214879A1 (enExample)
CA (2) CA3212301A1 (enExample)
HK (1) HK1218139A1 (enExample)
IL (6) IL326919A (enExample)
RU (2) RU2675928C2 (enExample)
WO (1) WO2014124172A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
SG11201700874SA (en) 2014-08-04 2017-03-30 Takeda Pharmaceuticals Co Method for proliferation of pancreatic progenitor cells
JP6705911B2 (ja) * 2016-04-14 2020-06-03 ヤンセン バイオテツク，インコーポレーテツド 多能性幹細胞の中腸内胚葉細胞への分化
ES2973213T3 (es) * 2016-05-18 2024-06-19 Univ Keio Medio de cultivo celular para cultivo de organoide, método de cultivo y organoide
US11746331B2 (en) 2017-01-27 2023-09-05 Kaneka Corporation Endodermal cell population, and method for producing cell population of any of three germ layers from pluripotent cell
EP3638205A4 (en) 2017-06-14 2021-03-17 Semma Therapeutics, Inc. DEVICES AND METHODS FOR ADMINISTERING THERAPEUTICS
JP2020527956A (ja) * 2017-07-21 2020-09-17 センマ・セラピューティクス・インコーポレーテッド 幹細胞由来の膵臓ベータ細胞の再凝集
US20210292708A1 (en) * 2018-08-03 2021-09-23 Kyoto University Cell production method
TWI862513B (zh) * 2018-09-19 2024-11-21 日商千紙鶴治療公司 包含胰島素產生細胞之細胞集團、包含該細胞集團之醫藥、其用途及製造方法
JP7555975B2 (ja) 2019-05-31 2024-09-25 ダブリュ．エル．ゴア アンド アソシエイツ，インコーポレイティド 生体適合性メンブレン複合体
WO2020243666A1 (en) 2019-05-31 2020-12-03 W. L. Gore & Associates, Inc. A biocompatible membrane composite
JP2022534545A (ja) 2019-05-31 2022-08-01 ダブリュ．エル．ゴア アンド アソシエイツ，インコーポレイティド 生体適合性メンブレン複合体
CA3257300A1 (en) 2019-05-31 2025-06-12 W. L. Gore & Associates, Inc. Cell encapsulation devices with controlled oxygen diffusion distances
EP4647080A3 (en) 2020-07-31 2026-02-18 Vertex Pharmaceuticals Incorporated Differentiation of pancreatic endocrine cells
US20260097083A1 (en) * 2022-09-26 2026-04-09 Kyoto University Method for producing pancreatic endoderm cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1165113E (pt) * 1999-04-06 2008-09-23 Genentech Inc Utilização de ligandos de receptor erbb no tratamento da diabetes
US6759039B2 (en) * 2000-06-30 2004-07-06 Amcyte, Inc. Culturing pancreatic stem cells having a specified, intermediate stage of development
CA2435826A1 (en) * 2001-01-24 2002-08-01 The Government Of The United States Of America Differentiation of stem cells to pancreatic endocrine cells
EP1941032A2 (en) * 2005-10-14 2008-07-09 Regents Of The University Of Minnesota Differentiation of non-embryonic stem cells to cells having a pancreatic phenotype
WO2007143193A1 (en) * 2006-06-02 2007-12-13 University Of Georgia Research Foundation, Inc. Pancreatic and liver endoderm cells and tissue by differentiation of definitive endoderm cells obtained from human embryonic stems
JP2012508584A (ja) * 2008-11-14 2012-04-12 ヴィアサイト，インコーポレイテッド ヒト多能性幹細胞由来膵臓細胞のカプセル化
ES2849181T3 (es) * 2009-04-22 2021-08-16 Viacyte Inc Composiciones celulares derivadas de células reprogramadas desdiferenciadas
US9109245B2 (en) * 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
CN107603943B (zh) * 2009-04-27 2019-10-11 威盛细胞有限公司 支持多能细胞生长的小分子和其方法
EP2436397B1 (en) * 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component

Also Published As

Publication number Publication date
RU2018144412A (ru) 2019-03-25
JP7550830B2 (ja) 2024-09-13
HK1218139A1 (zh) 2017-02-03
IL326919A (en) 2026-05-01
RU2675928C2 (ru) 2018-12-25
JP2016506736A (ja) 2016-03-07
IL239953B (en) 2021-05-31
CA2898431C (en) 2023-10-17
JP6517702B2 (ja) 2019-05-22
AU2014214879A1 (en) 2015-07-30
IL290717B2 (en) 2024-10-01
RU2754089C2 (ru) 2021-08-26
IL311689A (en) 2024-05-01
AU2022200075A1 (en) 2022-02-03
AU2019201314B2 (en) 2021-10-14
RU2015131279A (ru) 2017-03-13
RU2018144412A3 (enExample) 2020-02-14
AU2019201314A1 (en) 2019-03-14
CA2898431A1 (en) 2014-08-14
JP2019146578A (ja) 2019-09-05
WO2014124172A1 (en) 2014-08-14
AU2026201562A1 (en) 2026-03-19
AU2023202507A1 (en) 2023-05-11
EP2954045A1 (en) 2015-12-16
IL283088A (en) 2021-06-30
JP6721752B2 (ja) 2020-07-15
IL239953A0 (en) 2015-08-31
JP2020178694A (ja) 2020-11-05
JP2025000625A (ja) 2025-01-07
IL311689B1 (en) 2025-08-01
AU2023202507B2 (en) 2025-12-04
IL283088B (en) 2022-04-01
IL321825A (en) 2025-08-01
IL290717A (en) 2022-04-01
JP7250731B2 (ja) 2023-04-03
IL311689B2 (en) 2025-12-01
JP2023017838A (ja) 2023-02-07
AU2022200075C1 (en) 2023-07-06
IL290717B1 (en) 2024-06-01
AU2022200075B2 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
US20240409900A1 (en) Cell encapsulation device comprising a pancreatic progenitor cell population
AU2023202507B2 (en) Cell compositions derived from dedifferentiated reprogrammed cells
AU2023201602B2 (en) In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (pec) and endocrine cells
EP2421957B1 (en) Cell compositions derived from dedifferentiated reprogrammed cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230908

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241217

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250131

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250131

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250131

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20250415

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250415

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250505

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250513

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250513

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250610

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250924

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250924